Mechanism Overview: IGF-1 as a Central Follicle Growth Factor
Insulin-like growth factor 1 (IGF-1) is a 70-amino acid polypeptide hormone that is structurally related to proinsulin and is one of the most potent stimulators of cell proliferation and survival in the hair follicle. IGF-1 is produced locally by dermal papilla cells and signals through the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase that activates the PI3K/Akt and Ras/MAPK pathways. The critical importance of IGF-1 for hair growth was established by studies showing that IGF-1 knockout mice die at birth with severe growth retardation and completely lack hair follicles, and that IGF-1 supplementation can rescue hair growth in vitro.
IGF-1 is not just a growth factor—it is a survival factor. In the hair follicle, IGF-1 suppresses the apoptotic cascade that drives catagen, promotes the proliferation of matrix keratinocytes that produce the hair shaft, and enhances the production of VEGF that supports perifollicular vascularization. Multiple hair growth treatments—including minoxidil, caffeine, and peppermint oil—have been shown to upregulate IGF-1 expression, suggesting that IGF-1 may be a common downstream effector of diverse anagen-promoting signals.
Detailed Mechanism: IGF-1 Signaling in the Hair Follicle
IGF-1 binds to the IGF-1 receptor (IGF-1R), a transmembrane receptor tyrosine kinase that dimerizes and autophosphorylates upon ligand binding. The activated receptor phosphorylates insulin receptor substrate 1 (IRS-1), which recruits and activates PI3K. PI3K converts PIP2 to PIP3, which activates PDK1 and subsequently Akt (protein kinase B). Akt promotes cell survival by phosphorylating and inactivating pro-apoptotic proteins (Bad, caspase-9) and by activating NF-κB, a transcription factor that promotes the expression of anti-apoptotic genes including Bcl-2 and Bcl-xL.
Simultaneously, IGF-1R activates the Ras/MAPK pathway through Shc-Grb2-SOS complex formation, leading to Ras activation, Raf recruitment, and the phosphorylation cascade MEK → ERK1/2. Activated ERK translocates to the nucleus and phosphorylates transcription factors including Elk-1 and c-Myc, promoting the expression of cell cycle genes that drive keratinocyte proliferation.
A study by Philpott et al. (1994), published in the Journal of Investigative Dermatology, was among the first to demonstrate that IGF-1 is needed for human hair follicle growth in organ culture. Removal of IGF-1 from the culture medium resulted in premature catagen entry and follicle regression, while IGF-1 supplementation maintained anagen and promoted hair shaft elongation. The effective concentration was 10-100 ng/mL, within the physiological range of IGF-1 in scalp tissue.
Detailed Mechanism: IGF-1 as a Catagen Suppressor
One of the most important functions of IGF-1 in the hair follicle is suppression of the catagen-promoting effects of TGF-β1 and other catagen-inducing factors. A study by Soma et al. (2002), published in the Journal of Investigative Dermatology, demonstrated that IGF-1 prevented TGF-β1-induced catagen in cultured human hair follicles. The mechanism involves Akt-mediated phosphorylation and inactivation of the transcription factor FoxO1, which is required for TGF-β1 gene expression. By inhibiting FoxO1, IGF-1/Akt signaling suppresses the TGF-β1 autoinduction loop that would otherwise drive progressive catagen.
IGF-1 also upregulates VEGF expression in dermal papilla cells through both HIF-1α-dependent and independent mechanisms, providing an additional pathway by which IGF-1 supports anagen through enhanced perifollicular vascularization. This IGF-1-VEGF connection explains why treatments that upregulate IGF-1 (such as minoxidil and peppermint oil) also increase VEGF.
Research Evidence: IGF-1 in Hair Loss and Treatment
Reduced IGF-1 expression has been documented in androgenetic alopecia. A study by Itami & Inui (2005), published in the Journal of Dermatological Science, found that dermal papilla cells from balding scalp produced significantly less IGF-1 than DP cells from non-balding scalp, and that this reduction correlated with the degree of follicle miniaturization. DHT was shown to suppress IGF-1 expression in DP cells, providing a direct link between androgen signaling and reduced growth factor production.
Conversely, multiple hair growth treatments upregulate IGF-1: Minoxidil increases IGF-1 expression in DP cells through KATP channel-mediated and HIF-1α-mediated mechanisms. Caffeine increases IGF-1 expression in DP cells through PDE inhibition and cAMP signaling. Peppermint oil increases IGF-1 expression through the VGluT2/TRPM8 pathway. Microneedling increases IGF-1 through wound healing pathways involving platelet degranulation and fibroblast activation. The convergence of multiple anagen-promoting treatments on IGF-1 upregulation strongly suggests that IGF-1 is a central effector of hair growth.
Exogenous IGF-1 administration has been studied in animal models. A study by Matthews et al. (1999) demonstrated that subcutaneous IGF-1 infusion stimulated hair growth in mice, but systemic IGF-1 administration carries risks including hypoglycemia and potential tumor promotion. Topical IGF-1 has been explored but is limited by poor skin penetration and rapid degradation. Recombinant IGF-1 is not available as a hair growth product.
Limitations and Evidence Gaps
While IGF-1 is clearly important for hair follicle growth, several limitations must be acknowledged. First, IGF-1 is a systemic hormone with effects on every tissue in the body—systemic IGF-1 modulation for hair growth purposes would carry unacceptable risks including tumor promotion, cardiac effects, and metabolic disruption. Second, the local IGF-1 concentration at the follicle depends on both DP production and IGF binding proteins (IGFBPs) that regulate IGF-1 bioavailability. There are six IGFBPs with different tissue distributions and regulatory mechanisms, and the IGFBP profile of the scalp may be as important as absolute IGF-1 levels. Third, while multiple treatments upregulate IGF-1, it is unclear whether IGF-1 upregulation is necessary for their efficacy or merely an associated finding.
Frequently Asked Questions
Can I take IGF-1 supplements for my hair? No. Oral IGF-1 is digested like any other protein and does not survive to reach target tissues. Recombinant IGF-1 is a prescription medication with serious side effects and is not approved for hair loss.
Does exercise increase IGF-1? Yes, resistance exercise increases systemic IGF-1 levels, but the increase is modest and the relevance to hair growth is unproven. Aerobic exercise may actually decrease IGF-1.
Why do multiple hair treatments all increase IGF-1? IGF-1 appears to be a common downstream effector of several anagen-promoting signaling pathways. This convergence makes IGF-1 a central node in the hair growth signaling network, but it also means that directly targeting IGF-1 (rather than upstream regulators) carries more systemic risk.
Conclusion
IGF-1 is a central growth and survival factor for the hair follicle, promoting matrix keratinocyte proliferation through PI3K/Akt and Ras/MAPK signaling, suppressing TGF-β1-mediated catagen through FoxO1 inhibition, and upregulating VEGF for perifollicular angiogenesis. Multiple proven hair growth treatments converge on IGF-1 upregulation, suggesting it is a common downstream effector. Reduced IGF-1 expression in balding dermal papilla cells—partly mediated by DHT—may contribute to the progressive miniaturization seen in AGA. However, direct IGF-1 administration for hair growth is not feasible due to systemic risks and delivery challenges. The most practical approach to supporting IGF-1 activity at the follicle is through proven treatments that upregulate IGF-1 as part of their mechanism of action.